Trial
NCT04903054
Selective CD28 Blockade in Renal Transplant Recipients
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Bristol-Myers Squibb; PPD Development, LP
Condition
Kidney Transplantation
Intervention
Lulizumab
Why stopped
Limited period of availability of a supply of the study drug and difficulties in enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-22